Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician's choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial.

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2023
This article has no abstract
Epistemonikos ID: 798e43fa79d7a2b61fcb3e8f23c4349499216caa
First added on: Feb 19, 2025